# Katherine B. Peters

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/katherine-b-peters/

## Facts

| Field | Value |
| --- | --- |
| Citations | 9,682 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 46 |
| i10-index | 122 |
| Last Known Institution | Duke University |
| OpenAlex ID | https://openalex.org/A5071832983 |
| ORCID iD | 0000-0001-5110-3868 |
| Works | 441 |

## Researcher papers

- [Recurrent Glioblastoma Treated with Recombinant Poliovirus](https://scholariq.org/papers/recurrent-glioblastoma-treated-with-recombinant-poliovirus/)
- [Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma](https://scholariq.org/papers/vorasidenib-in-idh1-or-idh2-mutant-low-grade-glioma/)
- [Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/central-nervous-system-cancers-version-3-2020-nccn-clinical-practice-guidelines/)
- [Rural–Urban Disparities in Cancer Outcomes: Opportunities for Future Research](https://scholariq.org/papers/rural-urban-disparities-in-cancer-outcomes-opportunities-for-future-research/)
- [Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial](https://scholariq.org/papers/vorasidenib-a-dual-inhibitor-of-mutant-idh1-2-in-recurrent-or-progressive-glioma/)
- [Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma](https://scholariq.org/papers/randomized-phase-ii-and-biomarker-study-of-pembrolizumab-plus-bevacizumab-versus/)
- [Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth.](https://scholariq.org/papers/inhibition-of-tumor-angiogenesis-using-a-soluble-receptor-establishes-a-role-for/)
- [NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017](https://scholariq.org/papers/nccn-guidelines-insights-central-nervous-system-cancers-version-1-2017/)
- [NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022](https://scholariq.org/papers/nccn-guidelines-insights-central-nervous-system-cancers-version-2-2022/)
- [Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial](https://scholariq.org/papers/vorasidenib-and-ivosidenib-in-idh1-mutant-low-grade-glioma-a-randomized/)
- [Caregiver burden by treatment and clinical characteristics of patients with glioblastoma](https://scholariq.org/papers/caregiver-burden-by-treatment-and-clinical-characteristics-of-patients-with/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [Cancer Research and Treatments](https://scholariq.org/topics/cancer-research-and-treatments/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Duke University](https://scholariq.org/institutions/duke-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.